Update From the Field of Renal Sympathetic Denervation

Townsend RR Mahfoud F Kandzari DE ; SPYRAL HTN-OFF MED Trial Investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017 8 28 [Epub ahead of print]

Krum H Schlaich M Whitbourn R . Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet. 2009;373:1275–1281.

Esler MD Krum H Sobotka PA . Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–1909.

Turner JR O’Brien E . Inferences beyond a study design’s grasp: a cautionary case study from the recent renal sympathetic denervation. Therapeutic Innovation & Regulatory Science. 2015;49:86–92.

Lee J Turner JR . Raising the bar in renal sympathetic denervation research and reporting. J Clin Hypertens (Greenwich). 2016;18:89–94.

Kandzari DE Kario K Mahfoud F . The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J. 2016;171:82–91.

Horton R . GBD 2010: understanding disease, injury, and risk. Lancet. 2013;380:2053–2054.

Das P Samarasekera U . The story of GBD 2010: a “super-human” effort. Lancet. 2013;380:2067–2070.

Lim SS Vos T Flaxman AD . A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2224–2260.

Turner JR Viera AJ Shimbo D . Ambulatory blood pressure monitoring in clinical practice: a review. Am J Med. 2015;128:14–20.

Turner JR . Patient and physician adherence in hypertension management. J Clin Hypertens (Greenwich). 2013;15:447–452.

White WB Turner JR Sica D . Scientific statement. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive Forum held in Bethesda, Maryland, USA, October 10th 2013. J Am Soc Hypertens. 2014;8:743–757.

Burnier M . Drug adherence in hypertension [published online ahead of print September 1, 2017]. Pharmacol Res.

Judd E Clahoun DA . Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28:463–468.

Cai A Calhoun DA . Resistant hypertension: an update of experimental and clinical findings. Hypertension. 2017;70:5–9.

Cai A Feng Y Zhou Y . A comprehensive review of an unmet public health issue: resistant hypertension. Clin Exp Hypertens. 2017;39:101–107.

Parati G Esler M . The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012; 33:1058–1066.

Gulati V White WB . Review of the state of renal nerve ablation for patients with severe and resistant hypertension. J Am Soc Hypertens. 2013;7:484–493.

Bhatt DL Kandzari DE O’Neill WW . SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–1401.

Ioannidis JP Evans SJ Gøtzsche PC ; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–788.

Turner JR Karnad DR Kothari S . Cardiovascular Safety in Drug Development and Therapeutic Use: New Methodologies and Evolving Regulatory Landscapes. Gewerbestrasse, Switzerland:, 2017.

FDA. The Sentinel Initiative: National Strategy for Monitoring Medical Product Safety. https://www.fda.gov/downloads/Safety/FDAsSentinelInitiative/UCM124701.pdf. Published May 2008. Accessed September 25, 2017.

Weber MA Kirtane A Mauri L . Renal denervation for the treatment of hypertension: making a new start, getting it right. J Clin Hypertens (Greenwich). 2015;17:743–750.

White WB Galis Z Henegar J . Device therapy for hypertension: pathways for moving development forward. Proceedings from an American Society of Hypertension Interactive Forum held in Bethesda, Maryland, USA, June 26th 2014. J Am Soc Hypertens. 2015;9: 341–350.

Turner JR O’Brien E . Diagnosis and treatment of resistant hypertension: the critical role of ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2013;15:868–873.

Azizi M . Catheter-based renal denervation for treatment of hypertension [published online ahead of print August 28, 2017]. Lancet. [Epub ahead of print]